查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2017490

阿兹海默症（AD）：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

Alzheimer's Disease (AD) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 158 Pages | 商品交期: 2-3个工作天内

价格
简介目录

市场概览

  • 阿兹海默症市场正在经历重大变革，其驱动力是疾病修正治疗的出现和广泛应用。
  • 美国确诊患者数量正以 5% 的复合年增长率增长，形成了一个巨大且持续增长的潜在市场。
  • 法国阿兹海默症市场预计将从 2025 年的 2,700 万美元成长到 2035 年的 9.78 亿美元。

阿兹海默症（AD）概述

阿兹海默症（AD）是失智症的主要病因，约占所有失智症病例的60%至80%。它是进行性神经退化性疾病，其特征是认知能力下降、记忆力减退和功能衰退，最终导致完全依赖他人照顾。

这种疾病的特征主要体现在大脑的三个病理特征：

1. 淀粉样斑块 - 由淀粉样β片段组成的细胞外蛋白质聚集体。

2. 神经纤维缠结（NFTs）－细胞内过度磷酸化的Tau蛋白积累

3. 突触和神经细胞的丧失－这会破坏神经细胞之间的通讯，导致进行性认知能力下降。

这些病理变化将阿兹海默症（AD）与其他失智症（例如路易氏体失智症和血管性失智症）区分开来，儘管其他病理变化也可能同时存在，这种情况被称为混合型失智症。 AD主要影响老年人，且罹病风险随年龄增加而显着增加。临床上，此疾病会从轻度认知障碍（MCI）进展为中度至重度失智症。

近期的进展已经将治疗模式从单纯的症状治疗转变为针对淀粉样蛋白病理的疾病修正治疗（DMT），这代表了阿兹海默症治疗前景的重大转变。

主要亮点

  • 预计到 2025 年，美国阿兹海默症人数将大幅增加至 2035 年的 490 万人，呈现强劲的成长动能（年复合成长率超过 5%）。
  • 阿兹海默症（AD）仍然是一种负担沉重的慢性疾病，对临床、经济和看护者都有重大影响。
  • 儘管患者数量众多，但早期诊断仍不足，限制了及时介入和疾病修正治疗的引入。
  • 治疗模式正从症状治疗（胆碱酯酶抑制剂、NMDA拮抗剂）转向针对β-淀粉样蛋白路径的疾病修正治疗。
  • 早期患者（MCI/轻度阿兹海默症）是新兴治疗方法的主要目标族群，并推动了细分和治疗优先顺序的确定。

格式化和更新讯息

  • 详细报告（PDF）
  • 市场预测模型（基于微软Excel）
  • 流行病学数据（MS Excel，互动式工具）
  • 高阶主管洞察（PPT简报）
  • 其他功能：定期更新、自订和顾问支援。
  • 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

  • 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
  • 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
  • 未来十年市场收入和病患份额的预测是多少？
  • 哪些因素对市场趋势影响最大？
  • 受访专家对目前和新兴的治疗方法有何看法？
  • 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
  • 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
  • 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

  • G8
    • 我们
    • EU5
      • 法国
      • 德国
      • 义大利
      • 西班牙
      • 英国
    • 日本
    • 中国

大公司

  • Hoffmann-La Roche
  • Halia Therapeutics, Inc.
  • Novo Nordisk A/S
  • BeyondBio Inc.
  • Ono Pharmaceutical Co. Ltd
  • Eli Lilly and Company
  • Regeneration Biomedical, Inc.
  • Keymed Biosciences Co.Ltd
  • Amydis Inc.
  • ScandiBio Therapeutics AB
  • Karuna Therapeutics, Inc.
  • NSC-Therapeutics
  • Alzamend Neuro, Inc.
  • Annovis Bio Inc.
  • Bristol-Myers Squibb
  • NKGen Biotech, Inc.
  • Acumen Pharmaceuticals
  • Lexeo Therapeutics
  • Eisai Inc.
  • Cassava Sciences, Inc.
  • Merck Sharp &Dohme LLC
  • AriBio Co., Ltd.
  • Alector Inc.
  • Noah Pharmaceuticals, Inc.
  • Amylyx Pharmaceuticals Inc.
  • TauRx Therapeutics Ltd
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • AbbVie
  • Oligomerix, Inc
  • Life Molecular Imaging Ltd
  • Nuravax, Inc.
  • Green Valley（Shanghai）Pharmaceuticals Co., Ltd.
  • Novartis Pharmaceuticals
  • Beijing Joekai Biotechnology LLC
  • Vigil Neuroscience, Inc.
  • Allyx Therapeutics
  • T3D Therapeutics, Inc.
  • GlaxoSmithKline
  • Atridia Pty Ltd.
  • Alnylam Pharmaceuticals
  • Shanghai Hengrui Pharmaceutical Co., Ltd.
  • Akeso
  • Medesis Pharma SA
  • Avid Radiopharmaceuticals
  • CereMark Pharma, LLC
  • Araclon Biotech SL
  • Luye Pharma Group Ltd.

目录

第一章：主要调查结果及分析师说明

  • 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

  • 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

  • 重点
  • 发病率/盛行率
  • 已确诊并接受药物治疗的患者人数
  • 合併症
  • 其他相关患者群

第四章 市场规模及预测

  • 重点
  • 市场驱动因素与限制因素
  • 按药物类别分類的趋势
  • 各国具体趋势

第五章 竞争情势

  • 目前疗法
    • 重点
    • 诊断和治疗过程/演算法
    • 主要疗法概述及KOL洞察
  • 新兴疗法
    • 重点
    • 值得关注的后期新疗法—概述、市场上市预期和KOL洞察
    • 值得关注的早期研发管线

第六章：未满足的需求与目标产品分析

  • 主要未满足的需求以及透过新兴疗法实现的未来可能性
  • TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

简介目录

Alzheimer's Disease (AD) Market Outlook

Thelansis's "Alzheimer's Disease (AD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alzheimer's Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Alzheimer's Disease (AD) Overview

Alzheimer's Disease (AD) is the foremost cause of dementia, accounting for approximately 60-80% of all dementia cases. It is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and functional deterioration, ultimately leading to complete dependency.

The disease is defined by three key pathological features within the brain:

1. Amyloid plaques - extracellular protein aggregates composed of amyloid-beta fragments

2. Neurofibrillary tangles (NFTs) - intracellular accumulations of hyperphosphorylated tau protein

3. Synaptic and neuronal loss - resulting in disruption of communication between neurons and progressive cognitive decline

These pathological changes distinguish AD from other forms of dementia such as Lewy body disease and cerebrovascular dementia, although coexisting pathologies may occur, a condition referred to as mixed dementia. AD primarily affects the elderly population, with risk increasing significantly with age. Clinically, the disease progresses from mild cognitive impairment (MCI) to moderate and severe dementia.

Recent advances have shifted the treatment paradigm from purely symptomatic management toward disease-modifying therapies (DMTs) targeting amyloid pathology, marking a significant transformation in the AD treatment landscape.

Key Highlights

  • The diagnosed Alzheimer's population in the United States is projected to grow significantly, increasing from 3.0 million in 2025 to 4.9 million by 2035, reflecting a strong growth trajectory (5%+ CAGR).
  • AD remains a high-burden chronic disease, with substantial clinical, economic, and caregiver impact.
  • Despite large patient numbers, early-stage diagnosis remains suboptimal, limiting timely intervention and uptake of disease-modifying therapies.
  • The treatment paradigm is shifting from: Symptomatic therapies (cholinesterase inhibitors, NMDA antagonists) toward Disease-modifying therapies targeting amyloid-beta pathways
  • Early-stage (MCI/mild AD) patients represent the primary target population for emerging therapies, driving segmentation and treatment prioritization.

Market Overview

  • The Alzheimer's market is undergoing a significant transformation, driven by the emergence and adoption of disease-modifying therapies.
  • The diagnosed patient pool is expanding at 5% CAGR, creating a large and growing addressable market of the US.
  • The Alzheimer's market in France is projected to grow from $27M in 2025 to $978M by 2035

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

  • Hoffmann-La Roche
  • Halia Therapeutics, Inc.
  • Novo Nordisk A/S
  • BeyondBio Inc.
  • Ono Pharmaceutical Co. Ltd
  • Eli Lilly and Company
  • Regeneration Biomedical, Inc.
  • Keymed Biosciences Co.Ltd
  • Amydis Inc.
  • ScandiBio Therapeutics AB
  • Karuna Therapeutics, Inc.
  • NSC-Therapeutics
  • Alzamend Neuro, Inc.
  • Annovis Bio Inc.
  • Bristol-Myers Squibb
  • NKGen Biotech, Inc.
  • Acumen Pharmaceuticals
  • Lexeo Therapeutics
  • Eisai Inc.
  • Cassava Sciences, Inc.
  • Merck Sharp & Dohme LLC
  • AriBio Co., Ltd.
  • Alector Inc.
  • Noah Pharmaceuticals, Inc.
  • Amylyx Pharmaceuticals Inc.
  • TauRx Therapeutics Ltd
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • AbbVie
  • Oligomerix, Inc
  • Life Molecular Imaging Ltd
  • Nuravax, Inc.
  • Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
  • Novartis Pharmaceuticals
  • Beijing Joekai Biotechnology LLC
  • Vigil Neuroscience, Inc.
  • Allyx Therapeutics
  • T3D Therapeutics, Inc.
  • GlaxoSmithKline
  • Atridia Pty Ltd.
  • Alnylam Pharmaceuticals
  • Shanghai Hengrui Pharmaceutical Co., Ltd.
  • Akeso
  • Medesis Pharma SA
  • Avid Radiopharmaceuticals
  • CereMark Pharma, LLC
  • Araclon Biotech S.L.
  • Luye Pharma Group Ltd.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies - profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)